You are viewing an incomplete version of our website. Please click to reload the website as full version.

Browse our anti-VEGFR2 (KDR) Antibodies

Full name:
anti-Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) Antibodies (KDR)
On www.antibodies-online.com are 719 Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) Antibodies from 44 different suppliers available. Additionally we are shipping VEGFR2 Kits (90) and VEGFR2 Proteins (63) and many more products for this protein. A total of 897 VEGFR2 products are currently listed.
Synonyms:
6130401C07, CD309, fk52c05, flk, flk-1, FLK/KDR, flk1, flk1b, kdr, kdra, kdrb, Krd-1, Ly73, si:busm1-205d10.1, si:ch211-254j6.1, si:ch211-278f21.4, sVEGFR-2, VEGFR, Vegfr-2, vegfr2, vegfr4, vegr2, wu:fc31a09, wu:fk52c05
list all antibodies Gene Name GeneID UniProt
KDR 16542  
KDR 25589 O08775
KDR 3791 P35968

Show all species

Show all synonyms

All available anti-VEGFR2 Antibodies

Go to our pre-filtered search.

Top referenced anti-VEGFR2 Antibodies

  1. Human Polyclonal VEGFR2 Primary Antibody for FACS, IF - ABIN391979 : Yilmaz, Kliche, Mayr-Beyrle, Fellbrich, Waltenberger: p38 MAPK inhibition is critically involved in VEGFR-2-mediated endothelial cell survival. in Biochemical and biophysical research communications 2003 (PubMed)
    Show all 4 references for ABIN391979

  2. Human Polyclonal VEGFR2 Primary Antibody for IHC (p), WB - ABIN181334 : Quinn, Peters, De Vries, Ferrara, Williams: Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. in Proceedings of the National Academy of Sciences of the United States of America 1993 (PubMed)
    Show all 4 references for ABIN181334

  3. Human Polyclonal VEGFR2 Primary Antibody for EIA, IHC (p) - ABIN358131 : Le Boeuf, Houle, Huot: Regulation of vascular endothelial growth factor receptor 2-mediated phosphorylation of focal adhesion kinase by heat shock protein 90 and Src kinase activities. in The Journal of biological chemistry 2004 (PubMed)
    Show all 3 references for ABIN358131

  4. Human Polyclonal VEGFR2 Primary Antibody for WB - ABIN783332 : Zeng, Sanyal, Mukhopadhyay et al.: Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration ... in The Journal of biological chemistry 2001 (PubMed)
    Show all 2 references for ABIN783332

  5. Human Polyclonal VEGFR2 Primary Antibody for IHC (p), WB - ABIN389564 : Wittko, Schänzer, Kuzmichev, Schneider, Shibuya, Raab, Plate: VEGFR-1 regulates adult olfactory bulb neurogenesis and migration of neural progenitors in the rostral migratory stream in vivo. in The Journal of neuroscience : the official journal of the Society for Neuroscience 2009 (PubMed)

  6. Human Polyclonal VEGFR2 Primary Antibody for IHC, ELISA - ABIN1531998 : Terman, Carrion, Kovacs, Rasmussen, Eddy, Shows: Identification of a new endothelial cell growth factor receptor tyrosine kinase. in Oncogene 1991 (PubMed)

  7. Human Monoclonal VEGFR2 Primary Antibody for EIA, FACS - ABIN155179 : Benzinger, Martiny-Baron, Reusch, Siemeister, Kley, Marmé, Unger, Massing: Targeting of endothelial KDR receptors with 3G2 immunoliposomes in vitro. in Biochimica et biophysica acta 2000 (PubMed)

  8. Cow (Bovine) Polyclonal VEGFR2 Primary Antibody for IHC, WB - ABIN2792307 : Ohsaka, Hirota-Komatsu, Shibata, Ezaki, Shinohara, Yoshida: Specific association of increased vascular endothelial growth factor expression and its receptors with macrophage differentiation of HL-60 leukemia cells. in Biochemical and biophysical research communications 2008 (PubMed)

More Antibodies against VEGFR2 Interaction Partners

Rainbow Trout (Oncorhynchus mykiss) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. These results indicate that VEGF-C (show VEGFC Antibodies)-induced MSC (show MSC Antibodies) osteogenesis is mediated through VEGFR2 and VEGFR3 (show FLT4 Antibodies), and followed the activation of the ERK (show MAPK1 Antibodies)/RUNX2 (show RUNX2 Antibodies) signaling pathway.

Mouse (Murine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Intronic Flk1 genetic enhancer element directs arterial-specific expression via RBPJ (show RBPJ Antibodies)-mediated venous repression.

  2. Endothelial SCUBE2 may be a novel coreceptor for VEGFR2 and potentiate VEGF-induced signaling in adult angiogenesis.

  3. VEGFR2 signaling is necessary to maintain the integrity of the intestinal mucosal microvasculature during the postnatal period and lack of VEGFR2 signaling predisposes to NEC in neonatal mice.

  4. First-in-class selective PET tracers for imaging VEGFR-1 (show FLT1 Antibodies) and VEGFR-2 were constructed and successfully validated in an orthotopic murine tumor model.

  5. data for the first time demonstrate a calpain/PTP1B/VEGFR2 negative feedback loop in the regulation of VEGF-induced angiogenesis. Modulation of local PTP1B and/or calpain activities may prove beneficial in the treatment of impaired wound healing in diabetes.

  6. We found that bevacizumab reduced airway hyper-responsiveness (AHR (show AHR Antibodies)) and airway inflammation induced by HDM (show HDAC3 Antibodies). In addition, HDM (show HDAC3 Antibodies) exposure promoted expression of VEGF (show VEGFA Antibodies), and caused AHR (show AHR Antibodies), disruptions of the epithelial barrier, and airway inflammation. Bevacizumab ameliorated AHR (show AHR Antibodies) and the release of Th2 cytokines, thereby protecting the epithelial barrier. Our data suggest that bevacizumab may be a new therapeutic strategy for asthm

  7. Introduction of sVEGFR-2 suppressed lymphangiogenesis in primary lung cancer and also suppressed lymphogenic metastasis by inhibiting VEGF-C (show VEGFC Antibodies), followed by down-regulation of VEGFR-2, VEGFR-3 (show FLT4 Antibodies) and MMPs.

  8. VEGFB (show VEGFB Antibodies)-Induced Vascular Remodeling in Adipose Tissue Requires VEGF (show VEGFA Antibodies)/VEGFR2. VEGFB (show VEGFB Antibodies)-Induced Vascular Remodeling Improves Insulin (show INS Antibodies) Supply, Signaling, and Function in Obese Mice.

  9. demonstrated that Id1 (show ID1 Antibodies) and E2-2 (show TCF4 Antibodies) are critical regulators of EPCs function in vitro. Id1 (show ID1 Antibodies) interacts with E2-2 (show TCF4 Antibodies) and relieves the E2-2 (show TCF4 Antibodies)-mediated repression of FGFR1 (show FGFR1 Antibodies) and VEGFR2 expression to modulate EPCs functions

  10. Data suggest that expression of Notch-1 (show NOTCH1 Antibodies) receptor in endothelial progenitor cells (EPC (show TCF21 Antibodies)) in bone marrow is up-regulated in diabetic angiopathy (DA); signaling in EPC (show TCF21 Antibodies) via Notch-1 (show NOTCH1 Antibodies) receptor and VEGFA (show VEGFA Antibodies)/VEGFR2 appears to be altered in DA.

Human Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. By simulating therapeutic strategies that target multiple nodes of the pathway such as Raf and SphK1, we conclude that combination therapy should be much more effective in blocking VEGF signaling to EKR1/2. The model has important implications for interventions that target signaling pathways in angiogenesis relevant to cancer, vascular diseases, and wound healing.

  2. Endothelial SCUBE2 may be a novel coreceptor for VEGFR2 and potentiate VEGF-induced signaling in adult angiogenesis.

  3. there was no immunohistochemical evidence for apoptosis or autophagy. Quantitative staining showed similar expression levels of the angiogenesis regulators VEGF-A (show VEGFA Antibodies), VEGF-receptor 2 and Angpt1 (show ANGPT1 Antibodies) (p = 0.11), but Angpt2 (show ANGPT2 Antibodies) was significantly lower in CKD children (p = 0.01).

  4. Our results indicate that VEGF (show VEGFA Antibodies) SNPs -2578C>A and -1154G>A increase endometriosis risk, whereas VEGF (show VEGFA Antibodies) +405G>C and VEGFR2 1192C>T are protective against disease development, with VEGFR2 1192C>T also reducing cyclical urinary symptoms. The combined analysis of VEGF (show VEGFA Antibodies)-VEGFR2 genotypes suggests a gene-gene interaction in endometriosis susceptibility.

  5. There is a differential expression of VEGFR2 and activation of the NF-kappa B (show NFKB1 Antibodies) between male and female HUVECs under hyperoxic conditions.

  6. Assessment of VEGFR-2/VEGFR-3 (show FLT4 Antibodies) on tumor samples might serve as a putative prognostic factor in renal cell carcinoma (show MOK Antibodies) cases, identifying a subset of patients that may benefit from antiangiogenic treatments targeting VEGFR receptors.

  7. There is no association between two single-nucleotide polymorphisms of KDR gene and the susceptibility to recurrent spontaneous abortion in women from south-east Iran.

  8. data for the first time demonstrate a calpain/PTP1B/VEGFR2 negative feedback loop in the regulation of VEGF-induced angiogenesis. Modulation of local PTP1B and/or calpain activities may prove beneficial in the treatment of impaired wound healing in diabetes.

  9. The expression intensity of FGFR1 (show FGFR1 Antibodies) and VEGFR2 was associated with MVD (show MVD Antibodies), and the expression of FGFR1 (show FGFR1 Antibodies) is one of the independent prognostic indicators for NSCLC.

  10. There were significant differences of the median of serum VEGFR-2 between hepatocellular carcinoma (HCC (show FAM126A Antibodies)), liver cirrhosis (LC) and chronic hepatitis (CH) compared with healthy subjects. There was significant correlation between VEGFR-2 and severity disease in LC and CH. The serum VEGFR-2 could be used as predictive factor of progressing CH to LC, but not HCC (show FAM126A Antibodies).

Pig (Porcine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Here we demonstrate that VEGF (show VEGFA Antibodies)-165 mediates MSC (show MSC Antibodies) differentiation into ECs via VEGFR-2-dependent induction of Sox18 (show SOX18 Antibodies), which ultimately coordinates the transcriptional upregulation of specific markers of the EC phenotype

  2. NOS (show NOS Antibodies) stimulation via PI3K, calpain proteases, and SIRT1 (show SIRT1 Antibodies)-dependent deacetylation downstream from VEGFR2 activation contributes to these vasodilator responses.

  3. we analyzed the expression and cellular distribution of Flt-1(VEGFR-1 (show FLT1 Antibodies)) and Flk-1 (KDR/VEGFR-2)in newborn piglet brain

  4. expression of FLK1, CD146 (show MCAM Antibodies) and microvessel density of angiogenesis at the first week of reperfused acute myocardial infarction.

  5. VEGF (show VEGFA Antibodies) supplementation at the late embryonic developmental stage might improve the developmental potential of both IVF (show SCN5A Antibodies) and somatic nuclear transfer preimplantation porcine embryos through its receptors.

  6. The VEGFR2 mRNA was only upregulated in early glomerulogenesis, suggesting that VEGFR2 is important for the vascular growth.

  7. increased placental expression of the VEGF receptor (show FLT1 Antibodies) system is associated with increased placental vascular density observed with the advancement of gestation in the pig

  8. VEGF ligand-receptor system may play an important role in the development and maintenance of the corpus luteum in pigs.

  9. VEGF (show VEGFA Antibodies)/Flk-1/Flt-1 (show FLT1 Antibodies) system is activated during myocardial ischemia reperfusion injury.

  10. Hemodialysis graft placement leads to early increases in wall shear stress, VEGF-A (show VEGFA Antibodies), pro-MMP-9 (show MMP9 Antibodies), MMP-2 (show MMP2 Antibodies), VEGFR-1 (show FLT1 Antibodies), VEGFR-2, and TIMP-1 (show TIMP1 Antibodies), which may contribute to the development of venous stenosis.

Cow (Bovine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. data for the first time demonstrate a calpain/PTP1B/VEGFR2 negative feedback loop in the regulation of VEGF-induced angiogenesis. Modulation of local PTP1B and/or calpain activities may prove beneficial in the treatment of impaired wound healing in diabetes.

  2. endothelial cells exposed to TGF-beta1 (show TGFB1 Antibodies) lose both tip and stalk cell identity, possibly mediated by loss of VEGFR2 signaling.

  3. These results suggest that non-dominant follicles maintain a greater concentration of the mRNA expression of both membrane and soluble VEGF receptors; but follicular dominance is related to a reduction in the mRNA expression of sVEGFR1 and sVEGFR2.

  4. Data suggest that galectin-1 (show LGALS1 Antibodies) and VEGFR-2 are expressed at mid-luteal stages in luteal cells of corpus luteum; galectin-1 (show LGALS1 Antibodies) binds directly to asparagine-linked glycans (N-glycans) on VEGFR-2 in luteal cells.

  5. MMP-1 (show MMP1 Antibodies) promotes VEGFR2 expression and proliferation of endothelial cells through stimulation of PAR-1 (show F2R Antibodies) and activation of NF-kappaB (show NFKB1 Antibodies)

  6. Vascular endothelial growth factor receptor-2 activates ADP-ribosylation factor 1 (show ARF1 Antibodies) to promote endothelial nitric-oxide synthase (show NOS3 Antibodies) activation and nitric oxide release from endothelial cells

  7. VEGFR2 mRNA expression was higher at the mid and late luteal stages than at the early I and early II luteal stages, and VEGFR2 protein was higher at the mid and late luteal stages than at estrus (P<0.05)

  8. Alterations in the expression of VEGF-A (show VEGFA Antibodies) and bFGF (show FGF2 Antibodies) systems suggest that angiogenic factors are involved in abnormal placental development in cloned gestations, contributing to impaired fetal development and poor survival rates.

  9. involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt (show AKT1 Antibodies) and endothelial nitric-oxide synthase (eNOS (show NOS3 Antibodies))

  10. Placenta growth factor (show PGF Antibodies) expression is regulated by both VEGF (show VEGFA Antibodies) and hyperglycaemia via VEGFR-2.

Rabbit Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Antenatal intratracheal VEGF (show VEGFA Antibodies) administration was associated with an increase in Flk-1 immunoreactivity.

Zebrafish Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

  1. Intronic Flk1 genetic enhancer element directs arterial-specific expression via RBPJ (show RBPJ Antibodies)-mediated venous repression.

  2. Ca(2 (show CA2 Antibodies)+) oscillations depended upon VEGF receptor-2 (Vegfr2) and Vegfr3 (show FLT4 Antibodies) in endothelial cells budding from the dorsal aorta (DA) and posterior cardinal (show CARD8 Antibodies) vein, respectively.

  3. Methylglyoxal acts on smaller blood vessels in zebrafish via the VEGF receptor (show FLT1 Antibodies) signaling cascade, thereby describing a new mechanism that can explain vascular complications under hyperglycemia and elevated MG concentrations.

  4. methylation of Lys (show LYZ Antibodies)(1041) promotes the activation of VEGFR-2 and that similar posttranslational modification could also regulate the activity of other receptor tyrosine kinases.

  5. Perturbation of the HSP70 (show HSPA1A Antibodies)-HSP90 (show HSP90 Antibodies) heat-shock protein axis stimulates degradation of endothelial VEGFR2.

  6. Data indicate that the increase in FLT1/sFLT1 (show FLT1 Antibodies) protein levels upon miR-10 (show LILRB2 Antibodies) knockdown inhibited the angiogenic behavior of endothelial cells largely by antagonizing vascular endothelial growth factor receptor 2 signaling: [miR10 (show LILRB2 Antibodies)]

  7. Early Flk1 expression may be induced by cooperative interactions between Gata (show GATA4 Antibodies), Tcf (show HNF4A Antibodies)/Lef, Cdx (show CDX1 Antibodies) and ER71/Etv2 (show ETV2 Antibodies) under the control of Bmp, Wnt (show WNT2 Antibodies) and Fgf signaling.

  8. Using 2 distinct pharmacologic VEGFR2 inhibitors the study shows that rap1b (show RAP1A Antibodies) and VEGFR2 act additively to control angiogenesis in vivo.

  9. Data show that flk1 is not required for proper vasculogenesis and hematopoiesis in zebrafish embryos; however, the disruption of flk1 impairs the formation or function of vessels generated by sprouting angiogenesis

  10. flk1 is a direct target of FoxH1 (show FOXH1 Antibodies); FoxH1 (show FOXH1 Antibodies) is involved in vessel formation in zebrafish.

VEGFR2 (KDR) Antigen Profile

Antigen Summary

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.

Alternative names and synonyms associated with VEGFR2 (KDR)

  • vascular endothelial growth factor receptor 2 (vegfr-2) antibody
  • kinase insert domain protein receptor (Kdr) antibody
  • kinase insert domain receptor (Kdr) antibody
  • kinase insert domain receptor (a type III receptor tyrosine kinase) (KDR) antibody
  • kinase insert domain receptor (a type III receptor tyrosine kinase) (Kdr) antibody
  • kinase insert domain receptor (a type III receptor tyrosine kinase) (kdr) antibody
  • kinase insert domain receptor like (kdrl) antibody
  • vascular endothelial growth factor receptor-2 (KDR) antibody
  • 6130401C07 antibody
  • CD309 antibody
  • fk52c05 antibody
  • flk antibody
  • flk-1 antibody
  • FLK/KDR antibody
  • flk1 antibody
  • flk1b antibody
  • kdr antibody
  • kdra antibody
  • kdrb antibody
  • Krd-1 antibody
  • Ly73 antibody
  • si:busm1-205d10.1 antibody
  • si:ch211-254j6.1 antibody
  • si:ch211-278f21.4 antibody
  • sVEGFR-2 antibody
  • VEGFR antibody
  • Vegfr-2 antibody
  • vegfr2 antibody
  • vegfr4 antibody
  • vegr2 antibody
  • wu:fc31a09 antibody
  • wu:fk52c05 antibody

Protein level used designations for KDR

vascular endothelial growth factor receptor 2 , VEGF receptor-2 , fetal liver kinase 1 , kinase NYK , protein-tyrosine kinase receptor flk-1 , soluble vascular endothelial growth factor receptor 2 , vascular endothelial growth factor receptor- 2 , vascular endothelial growth factor receptor-2 , vascular endothelial growth factor receptor-3 , FLK-1 , FLK1 kinase insert domain receptor (VEGF receptor 2) , FLK1 kinase insert domain receptor (a type III receptor tyrosine kinase) (VEGF receptor 2) , kinase insert domain protein receptor , fetal liver kinase-1 , protein-tyrosine kinase receptor Flk-1 , soluble VEGFR2 , tyrosine kinase growth factor receptor , flk-1 type VEGF receptor , VEGFR2 , flk-1 receptor , protein-tyrosine kinase , tyrosine kinase receptor , VEGF receptor-2/Flk-1 , FLK-1b , VEGFR-2 homolog B , fetal liver kinase 1b , kinase insert domain receptor (a type III receptor tyrosine kinase), b , kinase insert domain receptor-B , protein-tyrosine kinase receptor flk-1b , vascular endothelial growth factor receptor 2 homolog B , VEGFR-4 , kinase insert domain receptor-A , kinase insert domain receptor-like , vascular endothelial growth factor receptor 4 , vascular endothelial growth factor receptor kdr-like , vascular endothelial growth factor receptor type 2

GENE ID SPECIES
100136647 Oncorhynchus mykiss
16542 Mus musculus
25589 Rattus norvegicus
3791 Homo sapiens
397311 Sus scrofa
482154 Canis lupus familiaris
395323 Gallus gallus
407170 Bos taurus
100726761 Cavia porcellus
100008607 Oryctolagus cuniculus
554230 Danio rerio
796537 Danio rerio
443087 Ovis aries
Selected quality suppliers for anti-VEGFR2 (KDR) Antibodies
Did you look for something else?